This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $267,298 to the Dana-Farber Cancer Institute, Inc. (DFCI) to advance research on targeting the CDK4/6 pathway in translocation renal cell carcinoma (TRCC), an aggressive form of kidney cancer.
The two-year project aims to test the therapeutic potential of inhibiting the CDK4/6 pathway, alone or in combination with PI3K/mTOR inhibition, to treat TRCC. The researchers will evaluate the sensitivity of TRCC cell lines and preclinical models to CDK4/6 inhibitors, and examine biomarkers of response. This work seeks to provide a scientific rationale for clinical trials testing CDK4/6-targeted therapies for this unmet medical need in kidney cancer.
Generated 3/4/25, 6:29 AM